Browsing Tag
The Lancet
10 posts
Retatrutide development: Phase 3 results, 2027 FDA filing, TRIUMPH trials and what comes next
Eli Lilly and Company’s retatrutide programme has completed the core Phase 3 clinical package supporting planned submissions for obesity, knee osteoarthritis pain and obstructive sleep apnea. The investigational triple hormone receptor agonist is moving toward a U.S. filing in the first quarter of 2027 while additional studies test diabetes, cardiovascular and kidney outcomes, liver disease, chronic pain, maintenance treatment and its performance against tirzepatide.
CAPR jumps 15% as FDA gives deramiocel three more months to rescue Duchenne approval bid
CAPR jumps as FDA extends deramiocel review to November 22, giving Capricor more time to support its Duchenne upper limb approval case.
Is the gMG treatment race entering a lower-burden dosing phase?
Find out how Regeneron’s cemdisiran review could reshape generalized myasthenia gravis treatment, REGN stock sentiment and siRNA competition today!
Alzheimer’s blood test breakthrough raises hopes for earlier dementia risk detection
Alzheimer’s may start long before memory loss. Blood tests could shift dementia care from late diagnosis to earlier risk planning.
Can Kelun-Biotech and Merck turn sac-TMT into the first ADC plus immunotherapy standard in front-line lung cancer?
Merck needs life after Keytruda. Kelun-Biotech’s sac-TMT lung cancer data may show how the next oncology cycle takes shape.
ScreenPoint Medical bets on risk prediction and workflow AI after $16m funding boost
ScreenPoint Medical has raised $16 million to expand its breast imaging AI platform. Read why this funding could reshape screening and risk prediction.
Corcept Therapeutics (CORT) stock in focus as ROSELLA survival data strengthen Lifyorli launch in ovarian cancer
Corcept Therapeutics strengthened its Lifyorli launch with new ROSELLA survival data. Read what this means for CORT stock and ovarian cancer treatment.
Breakthrough results: Intensity Therapeutics’ INT230-6 delivers strong survival and immune response in phase 1/2 cancer trial
Find out how Intensity Therapeutics’ INT230-6 achieved 11.9-month survival and immune activation in metastatic cancer—read what this means for biotech investors.
Resmed earnings soar—Is this sleep tech giant the next big health stock to watch?
Find out how Resmed’s Q3 FY25 results and stock surge signal strength in the sleep tech market. Explore the bullish sentiment and investor strategy.
MeiraGTx’s rAAV8.hRKp.AIPL1 shows remarkable efficacy in treating severe retinal dystrophy
A gene therapy developed by MeiraGTx Holdings plc has demonstrated remarkable success in restoring vision to children born…